Table 1.
Patient, graft and transplant characteristics
| Variable | N |
|---|---|
| Number of patients | 515 |
| Median age in years (range), (IQR) | 48 (2–73), (33–59) |
| Males | 307 (60%) |
| Diagnosis | |
| Acute lymphoblastic leukemia | 90 (17%) |
| Acute myeloid leukemia | 213 (41%) |
| Chronic myeloid leukemia | 15 (3%) |
| Other Leukemia | 23 (4%) |
| Myelodysplastic syndrome | 70 (14%) |
| Hodgkin’s & Non-Hodgkin’s lymphoma | 94 (18%) |
| Other Malignancy1 | 10 (2%) |
| High risk disease | 204 (40%) |
| CMV Seropositive | 303 (59%) |
| Conditioning regimen intensity2 | |
| Myeloablative | 166 (33%) |
| Reduced intensity | 349(77%) |
| GvHD Prophylaxis3 | |
| Cyclosporine A/mycophenolate mofetil | 383 (74%) |
| Tacrolimus/sirolimus | 69 (13%) |
| Sirolimus/MMF | 39 (8%) |
| Other | 24 (4%) |
| Worst HLA Allele Match at -A, -B and -DRB1 | |
| 2/6 | 27 (5%) |
| 3/6 | 106 (21%) |
| 4/6 | 256 (50%) |
| 5/6 | 102 (20%) |
| 6/6 | 24 (5%) |
| HLA-C Matching Score | |
| 0 matches | 57 (11%) |
| 1 match | 62 (12%) |
| 2 matches | 211 (41%) |
| 3 matches | 108 (21%) |
| 4 matches | 77 (15%) |
| Gender mismatch of at least one unit | 373 (76%) |
| TNC Infused (×107/kg) Median (range), (IQR) | 4 (2–20), (3–5) |
| Variable | N |
| Year of Transplantation | |
| 2003–2005 | 127 (25%) |
| 2006–2009 | 231 (45%) |
| 2010–2014 | 157 (30%) |
| Follow-up in years Median (range), (IQR) | 5.9 (1.0–12.4), (3.2–8.2) |
Abbreviations: IQR, inter-quartile range; CMV, cytomegalovirus; GVHD, graft-vs-host disease; HLA, human leukocyte antigen; TNC, total nucleated cell dose.
Myeloma (n=7), plasma cell leukemia (n=2), and renal cell carcinoma (n=1)
Myeloablative regimen consisted of cyclophosphamide 60 mg/kg for 2 days and total body irradiation 1320 cGY (n=3) and fludarabine 25 mg/m2 for 3 days (n=168). The RIC regimens were: 1) cyclophosphamide 50 mg/kg for 1 day, fludarabine 40 mg/m2 for 5 days and total body irradiation 200 cGY with (n=81) or without equine anti-thymocyte globulin 15 mg/kg twice daily for 3 days (n=152), and 2) fludarabine 30 mg/m2 for 6 days and melphalan 100 mg/kg in 1 day and rabbit anti-thymocyte globulin 1.5 mg/kg for 4 doses in alternating days (n=86).
The other immune suppression regimens were tacrolimus/mycophenolate mofetil (n=15), sirolimus/ mycophenolate mofetil (n=5), tacrolimus/sirolimus/mycophenolate mofetil (n=3), and cyclosporine/prednisone (n=4).